Table 33 (abstract P321). Significant predictors of sustained clinical responses to ETN for 24 weeks
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two
Baseline characteristic | Sustained JIA ACR remission | Sustained JADAS71 remission | ||
|---|---|---|---|---|
n/N (%) | Odds Ratio (95% CI) | n/N (%) | Odds Ratio (95% CI) | |
BMI, kg/m2 | >18 vs ≤18 | >18 vs ≤18 | ||
- ≤18 | 23/46 (50) | 0.31 (0.14, 0.66) | 26/46 (57) | 0.41 (0.19, 0.85) |
- >18 | 19/81 (24) | 28/81 (35) | ||
Height, cm | >158 vs ≤158 | >158 vs ≤158 | ||
- ≤158 | 28/56 (50) | 0.25 (0.11, 0.54) | 31/56 (55) | 0.39 (0.19, 0.80) |
- >158 | 14/71 (20) | 23/71 (32) | ||
Age at onset, mo | ||||
- ≤91 | 24/41 (59) | >91 vs ≤91 | 23/41 (56) | >91 vs ≤91 |
- >91 | 18/86 (21) | 0.19 (0.08, 0.42) | 31/86 (36) | 0.44 (0.21, 0.94) |
12-week clinical outcome | ||||
JIA ACR status | Remission vs active disease | Remission vs active disease | ||
- Remission | 11/15 (73) | 6.83 (2.02, 23.09) | 12/15 (80) 42/108 (39) | 6.29 (1.67, 23.60) |
- Active disease | 31/108 (29) | |||
JADAS71 status | Remission vs active disease | Remission vs active disease | ||
- Remission | 14/18 (78) | 9.72 (2.94, 32.11) | 14/18 (78) 39/102 (38) | 5.65 (1.74, 18.41) |
- Active disease | 27/102 (27) | |||